嗜铬细胞瘤和副神经节瘤生长抑素受体显像与肽受体放射性核素治疗的应用进展

Advances in the somatostatin receptor-targeting imaging and peptide receptor radionuclide therapy for pheochromocytomas and paragangliomas

嗜铬细胞瘤和副神经节瘤(PPGL)是罕见的神经内分泌肿瘤,可导致心血管系统严重并发症。由于PPGL高度表达生长抑素受体(SSTR),因此SSTR显像,特别是以68Ga-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽(DOTATATE)为代表的生长抑素类似物PET/CT显像,已成为PPGL定位诊断以及全身转移评估的重要手段。转移性PPGL的治疗方法有限,^(177)Lu-DOTATATE肽受体放射性核素治疗(PRRT)为无法手术的PPGL患者提供了新的治疗选择,显示了良好的治疗效果。该文就SSTR显像与PRRT在PPGL诊疗中的应用进展进行综述。

Pheochromocytomas and paragangliomas(PPGL)are rare neuroendocrine tumors leading to serious complications in the cardiovascular system.As somatostatin receptor(SSTR)is highly expressed in PPGL,SSTR-targeting imaging,particularly PET/CT based on 68Ga-labelled somatostatin analog represented by 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-D-Phe1-Tyr3-Thr8-octreotide(DOTATATE),becomes an important tool for location and assessment of systemic metastases.Treatments for metastatic PPGL are limited.Peptide receptor radionuclide therapy(PRRT)with ^(177)Lu-DOTATATE provides a new therapeutic option for patients with inoperable PPGL and demonstrates satisfying efficacy.This article summarizes the advances of SSTR-targeting imaging and PRRT in the diagnosis and treatment of PPGL.